Editas Medicine

@editasmed

At Editas Medicine, we are harnessing the potential of CRISPR gene editing to develop medicines for people living with serious diseases

Cambridge, MA and Boulder, CO

Editas Medicine
@editasmed
Sep 14
Last week, Editas participated in fireside chats at the Wells Fargo Healthcare Conference and Cantor Global Healthcare Conference, sharing updates on EDIT-401 and connecting with the wider healthcare and investment communities. Listen here: bit.ly/4r3c2d4. #invivo
Editas Medicine
@editasmed
Sep 9
Tomorrow, we’ll be participating in a fireside chat at the 2026 Cantor Global Healthcare Conference at 3:55 p.m. ET. Tune in here: bit.ly/4dbvZbP. #geneediting #cardiovasculardisease #firesidechat
Editas Medicine
@editasmed
Sep 8
We’re thrilled to welcome Dan Ory, M.D., as Chief Medical Officer at Editas Medicine. Dr. Ory brings decades of experience in cardiovascular disease, genetic medicines, and clinical development as we advance EDIT-401 toward the clinic. Read more: bit.ly/4y1Mwb3 #invivo
Editas Medicine
@editasmed
Sep 8
#NEWS: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer. Read the press release for details: bit.ly/4y1Mwb3. #geneediting #cardiovasculardisease #leadership
Editas Medicine
@editasmed
Sep 4
On Tuesday, we’ll be participating in a fireside chat at the Wells Fargo Healthcare Conference at 4:30 p.m. ET. Tune in here: bit.ly/4i4kbvA. #invivo #cardiovasculardisease #firesidechat